Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-directed RNA polymerase III (Pol III) is a complex, 17-subunit enzyme responsible for the transcription of essential small, non-coding RNAs, including transfer RNAs (tRNAs), 5S ribosomal RNA (rRNA), and U6 small nuclear RNA [UniProt: P05423, PubMed: 22225831]. It plays a pivotal role in cellular homeostasis by regulating the supply of components necessary for protein synthesis and is tightly controlled by major growth-signaling pathways [PubMed: 20159563]. Dysregulation of Pol III is a hallmark of many cancers, where its activity is often hijacked by oncogenic proteins to support the high metabolic demands of tumor growth [PubMed: 28220037]. Beyond oncology, genetic mutations in Pol III subunits lead to severe neurodegenerative conditions, such as hypomyelinating leukodystrophy, highlighting its importance in nervous system development [PubMed: 21741540]. The complex is also a significant target in autoimmune diseases; specifically, anti-Pol III antibodies are diagnostic for systemic sclerosis and are linked to rapid skin thickening and renal crisis [PubMed: 20635355]. While direct therapeutic targeting of Pol III is challenging due to its essential nature, small-molecule inhibitors like ML-60218 are being explored for their potential to selectively curb the hypertrophic transcription seen in cancer cells [PubMed: 17110398].
Inhibition of RNA synthesis by binding to the catalytic core or interfering with promoter recruitment and assembly of the transcription initiation complex [PubMed: 17110398, PubMed: 22225831].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-directed RNA polymerase III complex (Pol III) (Pol III).